- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05146336
CytOSorb TreatMent Of Critically Ill PatientS Registry (COSMOS)
April 10, 2024 updated by: CytoSorbents, Inc
CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting
Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care
Study Overview
Status
Recruiting
Conditions
- Sepsis
- Burns
- Septic Shock
- Trauma
- Infectious Disease
- Pancreatitis
- Acute Respiratory Distress Syndrome
- Liver Transplant; Complications
- Drug Overdose
- Acute Liver Failure
- Cardiogenic Shock
- Rhabdomyolysis
- Acute on Chronic Liver Failure
- Hemophagocytic Lymphohistiocytoses
- Extracorporeal Life Support
- Postoperative Vasoplegic Syndrome
- Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)
- Postoperative Endocarditis
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
3000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marie-Christin Pawlik, PhD
- Phone Number: +49 30 654 99 145
- Email: cosmos@cytosorbents.com
Study Contact Backup
- Name: Robert Wilke
- Phone Number: +49 30 654 99 145
- Email: cosmos@cytosorbents.com
Study Locations
-
-
-
Aachen, Germany, 52074
- Not yet recruiting
- Universitätsklinikum Aachen
-
Principal Investigator:
- Philipp Hohlstein, MD
-
Bad Oeynhausen, Germany, 32545
- Recruiting
- Herz- und Diabeteszentrum Nordrhein-Westfalen
-
Principal Investigator:
- Thomas Kirschning, MD
-
Bochum, Germany, 44789
- Recruiting
- Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil Bochum
-
Principal Investigator:
- Andreas Baumann, MD
-
Bochum, Germany, 44791
- Recruiting
- Katholisches Klinikum Bochum, St. Josef-Hospital
-
Principal Investigator:
- Martin Bellgardt, MD
-
Essen, Germany, 45147
- Recruiting
- Universitätsklinikum Essen, Medizinische Intensivtherapie
-
Principal Investigator:
- Bartosz Tyczynski, MD
-
Essen, Germany, 45147
- Recruiting
- Universitätsklinikum Essen, Nephrologie
-
Principal Investigator:
- Andreas Kribben, MD, Prof
-
Essen, Germany, 45147
- Recruiting
- Universitätsklinikum Essen, Thorax- und Kardiovaskuläre Chirurgie
-
Principal Investigator:
- Matthias Thielmann, MD, Prof
-
Göttingen, Germany, 37075
- Recruiting
- Universitätsmedizin Göttingen, Herzzentrum Göttingen
-
Principal Investigator:
- Aschraf El-Essawi, MD, PD
-
Herford, Germany, 32049
- Recruiting
- Klinikum Herford
-
Principal Investigator:
- Dietrich Henzler, MD, Prof
-
Kassel, Germany, 34125
- Withdrawn
- Klinikum Kassel
-
Marburg, Germany, 35043
- Recruiting
- Universitätsklinikum Marburg
-
Principal Investigator:
- Julian Kreutz, MD
-
Mönchengladbach, Germany, 41063
- Recruiting
- Kliniken Maria Hilf
-
Principal Investigator:
- Athina Gavriil
-
München, Germany, 80636
- Recruiting
- Deutsches Herzzentrum München
-
Principal Investigator:
- Thomas Günther, MD, PD
-
München, Germany
- Recruiting
- LMU Klinikum München
-
Principal Investigator:
- Christina Scharf-Janßen, MD, PD
-
Oldenburg, Germany, 26133
- Recruiting
- Klinikum Oldenburg
-
Principal Investigator:
- Ulf Günther, MD, PD
-
Wiesbaden, Germany, 65199
- Recruiting
- Helios Dr. Horst Schmidt Kliniken Wiesbaden
-
Principal Investigator:
- Moritz Unglaube, MD
-
-
-
-
-
Roma, Italy, 00165
- Recruiting
- Ospedale Pediatrico Bambino Gesù
-
Principal Investigator:
- Gabriella Bottari, MD
-
San Giovanni Rotondo, Italy, 71013
- Recruiting
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
Principal Investigator:
- Filippo Aucella, MD
-
-
-
-
-
Lisboa, Portugal
- Not yet recruiting
- CHULC, Hospital Curry Cabral
-
Principal Investigator:
- Nuno Germano, MD
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitari Vall d'Hebron
-
Principal Investigator:
- Ricard Ferrer Roca, MD
-
Huelva, Spain
- Not yet recruiting
- Hospital Juan Ramón Jimenez
-
Principal Investigator:
- Mario Márquez Fernández
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Critically ill patients receiving CytoSorb therapy
Description
Inclusion Criteria:
- Planned OR actual CytoSorb® 300 mL device utilization
- Informed consent for prospective registry participation
Exclusion Criteria:
- Use of the CytoSorb® 300 mL device for antithrombotic removal only
- Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
- The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
ICU mortality
Time Frame: Through ICU discharge or date of death, whichever comes first [on average 7 days]
|
Through ICU discharge or date of death, whichever comes first [on average 7 days]
|
In-hospital mortality
Time Frame: Through hospital discharge or date of death, whichever comes first [on average 14 days]
|
Through hospital discharge or date of death, whichever comes first [on average 14 days]
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ricard Ferrer Roca, MD, Hospital Vall d'Hebron
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 22, 2022
Primary Completion (Estimated)
June 1, 2032
Study Completion (Estimated)
September 1, 2032
Study Registration Dates
First Submitted
November 23, 2021
First Submitted That Met QC Criteria
November 23, 2021
First Posted (Actual)
December 6, 2021
Study Record Updates
Last Update Posted (Actual)
April 11, 2024
Last Update Submitted That Met QC Criteria
April 10, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Digestive System Diseases
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Substance-Related Disorders
- Respiratory Tract Diseases
- Lymphatic Diseases
- Respiration Disorders
- Lung Diseases
- Systemic Inflammatory Response Syndrome
- Inflammation
- Postoperative Complications
- Disease Attributes
- Disease
- Infant, Newborn, Diseases
- Liver Diseases
- Musculoskeletal Diseases
- Muscular Diseases
- Pancreatic Diseases
- Myocardial Infarction
- Infarction
- Lung Injury
- Infant, Premature, Diseases
- Histiocytosis, Non-Langerhans-Cell
- Histiocytosis
- Prescription Drug Misuse
- Drug Misuse
- End Stage Liver Disease
- Syndrome
- Liver Failure
- Hepatic Insufficiency
- Acute-On-Chronic Liver Failure
- Infections
- Communicable Diseases
- Shock
- Pancreatitis
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
- Shock, Cardiogenic
- Endocarditis
- Cytokine Release Syndrome
- Drug Overdose
- Liver Failure, Acute
- Lymphohistiocytosis, Hemophagocytic
- Vasoplegia
- Rhabdomyolysis
Other Study ID Numbers
- O06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Zagazig UniversityRecruitingSepsis-associated EncephalopathyEgypt
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
Clinical Trials on CytoSorb
-
Lund University HospitalCompletedLung Transplant Failure | Lung Transplant; ComplicationsSweden
-
Emma HanssonCytoSorbents, IncCompleted
-
Institutul Clinic FundeniCompleted
-
Centre Hospitalier Universitaire VaudoisCompletedMyocardial Ischemia | Heart Valve DiseasesSwitzerland
-
RWTH Aachen UniversityCompletedPostoperative Complications | Inflammatory ResponseGermany
-
Emanuela KellerCytoSorbents Europe GmbHTerminated
-
Hannover Medical SchoolCytoSorbents, IncRecruitingCytokine Release Syndrome | CAR-TGermany, Switzerland
-
Medical University of ViennaRecruiting
-
Radboud University Medical CenterCytoSorbents Europe GmbHCompletedSepsis | Immune Deficiency | Hemoperfusion | Blood PurificationNetherlands
-
Universitätsklinikum Hamburg-EppendorfCompleted